SAN FRANCISCO, October 18, 2017 /PRNewswire/ --
The global acute lymphocytic/lymphoblastic leukemia
therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new
report by Grand View Research, Inc. Increasing public and private
initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL),
rising number of bone marrow biopsies, and availability of other
treatment options are factors expected to increase the adoption of
ALL procedures. For instance, The Baby Friendly Initiative Program
by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative
approach between hospitals and healthcare institutions in
Canada, aim to provide free
diagnosis and treatment services to infants suffering from ALL, who
meet certain eligibility criteria.
(Logo:
http://photos.prnewswire.com/prnh/20160524/371361LOGO )
Furthermore, rising incidence of ALL is anticipated to boost the
market. The disease is prevalent among children below 5 years of
age. The risk of contracting ALL is the highest between the ages of
0 and 20. On the other hand, adults are also at a risk of
developing this condition. The median age of men diagnosed with
this condition is approximately 55 years.
Browse full research report with TOC on "Acute
Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis By
Therapy (Chemotherapy, Hyper-CVAD, Linker Regimen, Targeted
Therapy, Radiation Therapy), And Segment Forecasts, 2014 -
2025" at:
http://www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
Further Key Findings From the Report Suggest:
- Chemotherapy dominated the market in 2016 owing to its high
prescription rate, presence of a wide product portfolio, and easy
availability of products
- Targeted therapy is anticipated to be the most preferred
therapy in comparison to other types of therapies due to its
associated benefits such as target-specific action and its ability
to prevent collateral damage, leading to faster recovery
- Precursor B-ALL dominated the market in 2016 and is expected to
be the fastest growing segment during the forecast period due to
increasing prevalence of BCR-ABL and Burkitt leukemia, which are
its subtypes
- North America dominated the
market in 2016 owing to factors such as the increase in demand for
chemotherapy regimen such as CALGB 8811 and oncaspar in this
region
- Asia Pacific is anticipated to
be the fastest growing region with a lucrative CAGR during the
forecast period due to growing awareness about ALL. Furthermore,
the rising disposable income and presence of large population base
are some of the factors expected to propel the growth in this
region
- Key players in this industry are Erytech Pharma, Spectrum
Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme
Corporation
- Key players are focusing on strategies such as expansion of
product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and
QIAGEN entered into an agreement to use Next-Generation Sequencing
(NGS) technology to develop gene expression profiles for
immune-oncology therapies
Browse related reports by Grand View Research:
- Genetic Disease Diagnostic Market -
http://www.grandviewresearch.com/industry-analysis/genetic-disease-diagnostic-market
- Biotechnology Reagents Market -
http://www.grandviewresearch.com/industry-analysis/biotechnology-reagent-market
- Artemisinin Market -
http://www.grandviewresearch.com/industry-analysis/artemisinin-market
- Kidney Cancer Drugs Market -
http://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market
Grand View Research has segmented the global acute
Lymphocytic/Lymphoblastic leukemia therapeutics market on the basis
of therapy, type, and region:
- Therapy Outlook (Revenue, USD Million; 2014 -
2025)
- Chemotherapy
- Hyper-CVAD
- CALGB 8811 regimen
- Linker regimen
- Nucleoside Metabolic Inhibitors
- Oncaspar
- Targeted therapy
- Radiation Therapy
- Stem cell transplantation
- Type Outlook (Revenue, USD Million; 2014 - 2025)
- Philadelphia chromosome
- Precursor B-cell ALL
- T-cell ALL
- Regional Outlook (Revenue, USD Million; 2014 -
2025)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Read Our Blog By Grand View Research:
http://www.grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company
provides syndicated research reports, customized research reports,
and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant
and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com